Basic Information
| LncRNA/CircRNA Name | PANDAR |
| Synonyms | PANDAR, PANDA |
| Region | GRCh38_6:36673621-36675126 |
| Ensemble | ENSG00000281450 |
| Refseq | NR_109836 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR etc. |
| Sample | cervical squamous tissues, cell lines (HeLa, C33-A) |
| Expression Pattern | up-regulated |
| Function Description | The results of qRT-PCR showed that the expression level of PANDAR was signifcantly up-regulated in cervical cancer tissues compared with that in cancer-adjacent tissues. Statistical analysis showed that PANDAR expression was correlated with International Federation of Gynecology and Obstetrics (FIGO) staging, tumor size and tumor invasion degree. Kaplan-Meier survival analysis showed that the survival time of patients with highly expressed PANDAR was shorter than that of patients with lowly expressed PANDAR. Cox multivariate regression analysis showed that PANDAR could be used as an independent prognostic factor for patients with cervical cancer. CCK-8 results showed that interference in PANDAR signifcantly inhibited tumor cell proliferation. |
| Pubmed ID | 29131264 |
| Year | 2017 |
| Title | Upregulation of LncRNA PANDAR predicts poor prognosis and promotes cell proliferation in cervical cancer |
External Links
| Links for PANDAR | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |